Filed by Huntsman Corporation
pursuant to Rule 425 under the Securities Act of 1933
and deemed filed pursuant to Rule 14a-12 under
the Securities Exchange Act of 1934
Subject Company: Huntsman Corporation
Commission File No. 1-32427

HUNTSMAN

Enriching lives through innovation

Jefferies Industrials Conference

August 9, 2017

General Disclosure

Forward Looking Statements

This presentation includes "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward-looking statements include statements concerning our plans, objectives, goals, strategies, future events, future revenue or performance, capital expenditures, financing needs, plans or intentions relating to acquisitions, business trends and other information that is not historical information. When used in this presentation, the words "estimates," "expects," "anticipates," "projects," "plans," "intends," "believes," "forecasts," or future or conditional verbs, such as "will," "should," "could" or "may," and variations of such words or similar expressions are intended to identify forward-looking statements. All forward-looking statements, including, without limitation, management's examination of historical operating trends and data, are based upon our current expectations and various assumptions. Our expectations, beliefs and projections are expressed in good faith, and we believe there is a reasonable basis for them. However, there can be no assurance that management's expectations, beliefs and projections will be achieved. We assume no obligation to provide revisions to any forward-looking statements should circumstances change, except as required by applicable laws.

The forward-looking statements in this release are subject to uncertainty and changes in circumstances and involve risks and uncertainties that may affect the company's operations, markets, products, services, prices and other factors as discussed in the Huntsman companies' filings with the U.S. Securities and Exchange Commission. Significant risks and uncertainties may relate to, but are not limited to, volatile global economic conditions, cyclical and volatile product markets, disruptions in production at manufacturing facilities, reorganization or restructuring of Huntsman's operations, including any delay of, or other negative developments affecting, our merger with Clariant, the ability to implement cost reductions and manufacturing optimization improvements in Huntsman businesses and realize anticipated cost savings, and other financial, economic, competitive, environmental, political, legal, regulatory and technological factors.

All forward-looking statements attributable to us or persons acting on our behalf apply only as of the date made and are expressly qualified in their entirety by the cautionary statements included in this presentation. We undertake no obligation to update or revise forward-looking statements which may be made to reflect events or circumstances that arise after the date made or to reflect the occurrence of unanticipated events.

Supplemental Information

This presentation contains financial measures that are not in accordance with generally accepted accounting principles in the U.S. ("GAAP"), including EBITDA, adjusted EBITDA, adjusted EBITDA from discontinued operations, normalized EBITDA, adjusted net income (loss), adjusted diluted income (loss) per share and net debt. The Company has provided reconciliations of non-GAAP financial measures to the most directly comparable GAAP financial measures in the Appendix to this presentation.

Our financial statements and tax returns are prepared with certain components of inventory stated on the LIFO method for inventory valuation, and supplemental information is not intended to replace the primary published financial statements which include these inventories on a LIFO basis. Please refer to the primary published financial statements in our most recently filed Form 10-K and Forms 10-Q.

Near Term Priorities

Focused on free cash flow generation and debt reduction

- Greater than $450 million FCF expected in 2017 on a pre-Venator basis. Second half 2017 targeted to be greater than $150mm, without Venator
- Repaid $265 million of debt in 2017 as of the end of July 2017
- Since January 2016, including approximately $1.2 billion of Venator net proceeds excluding tax, we will have repaid over $2 billion of debt

Separate the Pigments & Additives Business (Venator)

- Venator IPO is completed and shares began trading August 3rd under the ticker VNTR
- Intend to use the over $1.2 billion in net proceeds excluding tax, from Venator to reduce Huntsman debt, which will reduce annual cash interest expense by ~$45 million
- Monetize remaining 75.4% ownership through secondary offerings in an orderly manner and dependent upon market conditions

Preparation for Merger of Equals with Clariant

- Cost synergy targets in excess of $400 million confirmed, creating in excess of $3.5 billion in value for shareholders
- Additional organic sales revenues of ~2% p.a. at ~ 20% adjusted EBITDA margin from complementary product portfolios in Performance Products / Care Chemicals / Natural Resources
- Antitrust filings and regulatory reviews are underway
- Shareholder meetings and closing targeted for December ‘17/January ‘18

Portfolio Composition[1]

Revenue[2]



2Q17 LTM[4]

Revenues
$7.6
billion

Adjusted EBITDA
$1.0
billion

Adjusted EBITDA[2][3]



End Markets[4]

2016 Revenues

Source: Management estimates



Adjusted EBITDA[3]

$ in millions



(1) Pro forma to exclude the Pigments & Additives business, which is treated as discontinued operations after the completion of Venator's IPO on August 8, 2017.
(2) Segment allocation is before Corporate and other unallocated items
(3) See Appendix for a reconciliation
(4) Excludes European surfactants business, which was sold to Innospec on December 30, 2016

HUNTSMAN

HUN EBITDA Growth in Key Specialty Markets

~46% EBITDA

MDI EBITDA



MDI Urethanes Contr. Margin and Volatility



19% EBITDA

Advanced Materials EBITDA



10% EBITDA

Amines EBITDA



Polyurethanes

MDI Urethanes End Markets

2016 Revenues   Source: Management Estimates



2Q17 LTM

Revenues
$3.8
billion

Adjusted EBITDA
$578
million

Revenues

2016 Revenues

MDI Competitive Intensity



Adjusted EBITDA History



HUNTSMAN

Polyurethanes – Focus on Driving Differentiation

75% of Sales

Differentiated Characteristics

- System sales or specialized MDI
- Technical solutions
- Lower volatility, less utilization dependent
- Higher cost to serve
- Higher long term average EBITDA
- ~10c/lb higher long term average unit contribution margins
- Downstream proximity

23% PORTFOLIO*

'Bolt on' acquisitions providing market access & technology platforms

IROGRAN, HAPC, NMG, PUR Systems, NINGWU, XID, XEMAX, gomet, TECNOELASTOMERI, IFS Chemicals Ltd

Global Reach, Local Proximity

* % of 2016 MDI EBITDA

HUNTSMAN

Performance Products

End Markets(1)

2016 Revenues — Source: Management Estimates



(1) Excludes European surfactants business, which was sold to Innospec in 2016

2Q17 LTM

Revenues(1)
$2.0
billion

Adjusted EBITDA(1)
$311
million

Revenues(1)

2016 Revenues



Huntsman Market Share

Product	Market Share	Peers
Amines		
Polyetheramines (Global)	>60%	BASF
Ethyleneamines (Global)	45%	Dow, Tosoh, Delamine
Ethanolamines (Americas)	20%	Dow, Ineos, Oxiteno
Morpholine/DGA (Americas & EMEA)	50%	BASF
Specialty PU Catalysts (Global)	40%	BASF, Evonik, Momentive
Maleic Anhydride (Americas & EMEA)	40%	Lanxess, Flint Hills, Polynt, Bartek

Adjusted EBITDA History(1)

$ in millions



HUNTSMAN

Three Key Businesses in Performance Products

~40% EBITDA

Amines

- Broadest product offering of any producer
- Fast growing markets (5-8%)
- Continued investment in capacity expansion to meet market growth

LTM Q117 Revenues



~20% EBITDA

Maleic Anhydride

- World's largest Maleic Anhydride producer with 12% of world capacity
- Global technology leader, lowest cost producer in NA and Europe
  - 75% share of licensing projects
  - Lowest cost butane-based process, benzene losing out



~15% EBITDA

Surfactants

- Assets in North America, Australia and India
- Backward integrated to EO in the US and Australia
- Only integrated player in specialty markets of agriculture, oilfield, fuel and lubes



HUNTSMAN

Advanced Materials

End Markets



2Q17 LTM

Revenues

$1.0

billion

Adjusted EBITDA

$215

million

Revenues



Competitive Landscape



Adjusted EBITDA History

Advance Materials

Focus on Growth



Textile Effects

End Markets



2Q17 LTM

Revenues
$0.8
billion

Adjusted EBITDA
$76
million

Revenues





Competitive Landscape



Adjusted EBITDA History





Textile Effects Portfolio Composition

Description

2011-2016 CAGR Volume Growth

Specialty (+11%)

- Proprietary technologies
- Fully aligned with industry trends (e.g., environmental sustainable)

Differentiated (+3%)

- Strong knowhow with some intellectual property
- Recognized brands
- Focus on margin management

Value (-4%)

- Progressively deselected
- Promoted as package offering with Specialty and differentiated portfolios
- Focus on cost optimization

2016 Portfolio



Demonstrated ability to grow profitably with strategy to drive to mid-teens EBITDA margins.

HUNTSMAN

HUNTSMAN CLARIANT

Creating a Global Specialty Chemical Leader

Select slides from the merger update and transaction overview presentation

General Disclosure

Cautionary Statement Regarding Forward-Looking Statements

This communication contains certain statements that are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended (the "Securities Act"), and Section 21E of the Securities Exchange Act of 1934, as amended. Clariant Ltd ("Clariant") and Huntsman Corporation ("Huntsman") have identified some of these forward-looking statements with words like "believe," "may," "could," "would," "might," "possible," "will," "should," "expect," "intend," "plan," "anticipate," "estimate," "potential," "outlook" or "continue," the negative of these words, other terms of similar meaning or the use of future dates. Forward-looking statements in this communication include, without limitation, statements about the anticipated benefits of the contemplated transaction, including future financial and operating results and expected synergies and cost savings related to the contemplated transaction, the plans, objectives, expectations and intentions of Clariant, Huntsman or the combined company and the expected timing of the completion of the contemplated transaction. Such statements are based on the current expectations of the management of Clariant or Huntsman, as applicable, are qualified by the inherent risks and uncertainties surrounding future expectations generally, and actual results could differ materially from those currently anticipated due to a number of risks and uncertainties. Neither Clariant nor Huntsman, nor any of their respective directors, executive officers or advisors, provide any representation, assurance or guarantee that the occurrence of the events expressed or implied in any forward-looking statements will actually occur. Risks and uncertainties that could cause results to differ from expectations include: uncertainties as to the timing of the contemplated transaction; uncertainties as to the approval of Huntsman's stockholders and Clariant's shareholders required in connection with the contemplated transaction; the possibility that a competing proposal will be made; the possibility that the closing conditions to the contemplated transaction may not be satisfied or waived, including that a governmental entity may prohibit, delay or refuse to grant a necessary regulatory approval; the effects of disruption caused by the announcement of the contemplated transaction making it more difficult to maintain relationships with employees, customers, vendors and other business partners; the risk that stockholder litigation in connection with the contemplated transaction may affect the timing or occurrence of the contemplated transaction or result in significant costs of defense, indemnification and liability; ability to refinance existing indebtedness of Clariant or Huntsman in connection with the contemplated transaction; other business effects, including the effects of industry, economic or political conditions outside of the control of the parties to the contemplated transaction; transaction costs; actual or contingent liabilities; disruptions to the financial or capital markets, including financing activities related to the contemplated transaction; and other risks and uncertainties discussed in Huntsman's filings with the U.S. Securities and Exchange Commission (the "SEC"), including the "Risk Factors" section of Huntsman's annual report on Form 10-K for the fiscal year ended December 31, 2016 and quarterly report on Form 10-Q for the six months ended June 30,2017. You can obtain copies of Huntsman's filings with the SEC for free at the SEC's website (www.sec.gov). Forward-looking statements included herein are made only as of the date hereof and neither Clariant nor Huntsman undertakes any obligation to update any forward-looking statements as a result of new information, future developments or otherwise, except as expressly required by law. All forward-looking statements in this communication are qualified in their entirety by this cautionary statement.

General Disclosure (Cont'd)

Important Additional Information and Where to Find It

NO OFFER OR SOLICITATION

This communication is not intended to and does not constitute an offer to sell or the solicitation of an offer to subscribe for or buy or an invitation to purchase or subscribe for any securities or the solicitation of any vote or approval in any jurisdiction, nor shall there be any sale, issuance or transfer of securities in any jurisdiction in contravention of applicable law. No offer of securities will be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act.

IMPORTANT ADDITIONAL INFORMATION WILL BE FILED WITH THE SEC

In connection with the contemplated transaction, Clariant intends to file a registration statement on Form F-4 with the SEC that will include the Proxy Statement/Prospectus of Huntsman. The Proxy Statement/Prospectus will also be sent or given to Huntsman stockholders and will contain important information about the contemplated transaction. INVESTORS AND SHAREHOLDERS ARE URGED TO READ THE PROXY STATEMENT/PROSPECTUS AND OTHER RELEVANT DOCUMENTS FILED OR TO BE FILED WITH THE SEC CAREFULLY WHEN THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT CLARIANT, HUNTSMAN, THE CONTEMPLATED TRANSACTION AND RELATED MATTERS. Investors and shareholders will be able to obtain free copies of the Proxy Statement/Prospectus (when available) and other documents filed with the SEC by Clariant and Huntsman through the website maintained by the SEC at www.sec.gov.

PARTICIPANTS IN THE SOLICITATION

Huntsman and its directors and executive officers may be deemed to be participants in the solicitation of proxies from Huntsman investors and shareholders in connection with the contemplated transaction. Information about Huntsman's directors and executive officers is set forth in its proxy statement for its 2017 Annual Meeting of Stockholders and its annual report on Form 10-K for the fiscal year ended December 31, 2016. These documents may be obtained for free at the SEC's website at www.sec.gov. Additional information regarding the interests of participants in the solicitation of proxies in connection with the contemplated transactions will be included in the Proxy Statement/ Prospectus that Huntsman intends to file with the SEC.

Merger Creates Substantial Long-Term Value

Strategic rationale

- Highly complementary product portfolios creating production set up and supply chain benefit opportunities in specific overlapping businesses. Performance Products / Care Chemicals / Natural Resources represent approx. 35% of overall sales
  - Meaningful opportunities for growth including cross-selling potential and new product applications
  - Complementary asset and geographic fit provides significant commercial opportunities and more global reach within established routes to market
  - Continuing to move downstream into specialties and more differentiated applications while taking advantage of a broad asset base
- Two strong specialty chemicals businesses with similar adjusted EBITDA margins at 17.2% including synergies when combined
- Unique opportunity by combining the best of two cultures – Huntsman's entrepreneurship and efficiency and Clariant's innovation and business excellence

Financial rationale

- High confidence in meeting synergy target in excess of $400m + $25m tax saving target, creating in excess of $3.5 billion in value for shareholders
- Additional organic sales revenues of ~2% p.a. at ~ 20% adjusted EBITDA margin from complementary product portfolios in Performance Products / Care Chemicals / Natural Resources
- Stronger balance sheet with pro forma leverage of under 1.5x, consistent higher cash flow, and lower financing costs
- More capital for organic growth, value creating add-on acquisitions and capital return

HUNTSMAN CLARIANT

Merger Implementation Update – according to plan

Progress

- ✓ Integration teams established, cost synergy targets in excess of \$400m plus \$25m of tax savings confirmed and additional revenue synergies revealed
  - Daily interaction - 13 primary work streams, 35 different working teams, 100+ individuals dedicated to optimizing synergy implementation and over-achievement; good cultural fit and working spirit
- ✓ Key antitrust regulatory filings submitted, including in the US, EU (preliminary filing) and China. Certain approvals in other jurisdictions already secured. No regulatory roadblocks expected to closing the deal
- ✓ Preliminary CFIUS filing submitted
- ✓ Venator initial public offering is now completed
  - Provides significant de-leveraging of HuntsmanClariant balance sheet – no proceeds to Venator itself

Targeting a December/January closing

Timeline



HUNTSMAN

Enriching lives through innovation

Appendix

HuntsmanClariant – Attractive and Balanced Portfolio

2016 Sales



2016 EBITDA



Combined Sales
$13.2bn

17.2%
***Combined EBITDA margin*[(1)]**

Combined EBITDA
$2.3bn [(1)]

Note: Based on 2016 business mixes. Segment breakdown excludes corporate costs. CHF converted at an average exchange rate of 0.988 USD/CHF. Huntsman is pro forma for the announced separation of its Pigments and Additives business, Venator.
(1) Includes $400 million in annual run-rate cost synergies.

HUNTSMAN CLARIANT

Attractive Specialty Chemical Portfolio with Strong Growth and EBITDA Margins

	Business	Highlights	Expected Growth	EBITDA Margin Target[1]
	Catalysis	*Market and technology leader in petrochemicals, syngas and chemicals catalysts*	6 – 7%	24 – 26%
	Advanced Materials	*One of the leading materials solution providers in highly qualified aerospace, automotive and electrical insulation markets*	4 – 6%	21 – 23%
	Care Chemicals	*Critical solutions provider to end-markets supported by secular lifestyle-driven megatrends*	4 – 5%	18 – 19%
	Performance Products	*Broad portfolio of innovative products serving growing end markets such as personal care, consumer and selected industrial markets*	5 – 7%[2]	18 – 20%
	Polyurethanes	*One of the leading global players in the high growth MDI industry. Strategic intent to drive portfolio further downstream and deliver high value, sustainable growth*	6 – 9%	16 – 18%
	Natural Resources	*Innovative, performance enhancing and tailored service solutions for the oil and gas industry as well as specialty products based on bentonite*	6 – 7%	15 – 17%
	Textile Effects	*One of the leading global textile dyes, chemicals and digital inks businesses*	5 – 7%	13 – 15%
	Plastics & Coatings	*Sector leading businesses of differentiated high performance products to a wide range of end-markets*	GDP	Steered for absolute EBITDA

Contributed by Clariant | Contributed by Huntsman

Source: Management estimates.
(1) Margin targets exclude synergies.
(2) Excludes upstream intermediates.

HuntsmanClariant – Balanced Geographic Footprint with Increased Strength in North America and China



North America (27% of sales)	China (11% of sales)
▪ Significantly increased presence for Clariant in North American markets	▪ One of the market leading international chemical companies
▪ Vertical integration benefiting from low cost raw materials	▪ Capitalizing from ongoing growth investments, building on manufacturing footprint with more than 20 locations
▪ Extends Huntsman's formulation expertise and downstream applications	▪ Strong local joint ventures, including two new polyurethane joint ventures coming online in 2018

Note: Based on 2016 sales mixes. Huntsman is pro forma for the announced separation of its Pigments and Additives business, Venator.

HUN Performance Products / CLN Care Chemicals & Natural Resources – Moving Products Downstream into Formulations

Region		% Sales in Region[1]	Raw Materials		Components	Formulations / Markets
North America	HUN	Performance Products 55% USD 1,033mn	EO	1,365 mlbs (620 ktes)	Surfactants	Oilfield Services
	CLN	Care Chemicals 19% CHF 270mn	PO	525 mlbs (240 ktes)	Amines	Personal Care Agriculture

Huntsman's Gulf Coast advantaged EO production and large commercial position in North America provides vertical integration for Clariant to mirror its European market leading position. Clariant's formulation technology allows Huntsman's component / intermediate products to be further differentiated.

Region		% Sales in Region[1]	Raw Materials		Components	Formulations / Markets
Europe	HUN	Performance Products 17% USD 322mn	EO	550 mlbs (250 ktes)	Surfactants	Oilfield Services Personal Care
	CLN	Care Chemicals 44% CHF 638mn			Amines	Agriculture

The combination of Huntsman's component products technology and Clariant's formulation technology will result in faster product development and a more complete product offering to customers.

[1] Pro forma adjusted for the sale of the European Surfactants business on December 30, 2016.

Estimated Annual Cost Synergies in Excess of $400mn

Procurement ~$150mn	Direct spend (~$50mn)	▪ Optimize purchasing on ~$5.5 billion of combined annual material supplies by bundling volume, renegotiating terms and conditions, insourcing of raw materials ▪ ~25% spend overlap of top 50 products and ~30% overlap in top 50 suppliers
	Indirect spend (~$100mn)	▪ Optimize annual combined spend of ~$3.6 billion supplies by bundling volume, standardization and renegotiating terms and conditions
Operational ~$250mn	Corporate Office, and Asset Consolidation (~$200mn)	▪ Streamlining of corporate and functional organization (HR, IT, Finance, etc.) including elimination of duplicated roles ▪ Integration of regional non operating assets (e.g. regional centers in the USA, South America, Europe, APAC) ▪ Leverage combined IT platforms
	Other Operational (~$50mn)	▪ Optimization of production ▪ Leveraging of best practices and functional excellence

Full $400 mn run rate to be achieved by end of 2019

Cash tax savings in excess of $25 million from optimizing the use of combined NOLs

Source: Management estimates.

Adjusted EBITDA Reconciliation

($ in millions)

	2Q15	3Q15	4Q15	1Q16	2Q16	3Q16	4Q16	1Q17	2Q17
Net Income	$ 39	$ 63	$ 9	$ 62	$ 94	$ 64	$ 146	$ 92	$ 183
Net income attributable to noncontrolling interests	(10)	(8)	(5)	(6)	(7)	(9)	(9)	(16)	(16)
Net income (loss) attributable to Huntsman Corporation	$ 29	$ 55	$ 4	$ 56	$ 87	$ 55	$ 137	$ 76	$ 167
Interest expense, net	53	49	47	50	50	52	50	48	47
Income tax expense (benefit)	34	49	(39)	27	32	(1)	29	23	45
Depreciation and amortization	99	103	102	100	109	113	110	106	108
Income taxes, depreciation and amortization in discontinued operations	1	(1)	(3)	(1)			(1)	(1)	1
Acquisition and integration expenses, purchase accounting adjustments	12	10	22	9	4	8	2	3	4
EBITDA from discontinued operations	1	1	3	2	1	1	2	2	
(Gain) loss on disposition of businesses/assets	1	-	1	-		(22)	(106)		(9)
Loss on early extinguishment of debt	20	8	-	-	2	1			1
Certain legal settlements and related expense	1	1	1	1	-	-	2		1
Plant incident remediation costs (credits), net	-	3	1	1	(7)	4	3	5	(2)
Expenses associated with merger	-	-							6
Amortization of pension and postretirement actuarial losses	19	19	18	16	17	16	16	22	22
Business separation costs	-	-	-	-	-	-	18	9	12
Restructuring, impairment, plant closing and transition costs (credits)	115	14	83	13	30	45	(6)	36	10
Adjusted EBITDA	385	311	240	274	325	272	256	329	413
Acquisition - ROC Performance Additives & TiO2[1]	-	-	-	-	-	-	-		
Sale of European differentiated surfactants business[2]	(6)	(5)	(4)	(7)	(8)	(7)	(6)	-	-
Proforma adjusted EBITDA	$ 379	$ 306	$ 236	$ 267	$ 317	$ 265	$ 250	$ 329	$ 413

	2010	2011	2012	2013	2014	2015	2016	2Q17 LTM
Net Income	$ 32	$ 254	$ 373	$ 149	$ 345	$ 126	$ 366	$ 485
Net income attributable to noncontrolling interests	(5)	(7)	(10)	(21)	(22)	(33)	(31)	(50)
Net income attributable to Huntsman Corporation	$ 27	$ 247	$ 363	$ 128	$ 323	$ 93	$ 335	$ 435
Interest expense, net	229	249	226	190	205	205	202	197
Income tax expense	29	109	169	125	51	46	87	96
Depreciation and amortization	404	439	427	446	445	399	432	437
Income taxes, depreciation and amortization in discontinued operations	11	(5)	2	-	(2)	(2)	(2)	(1)
Acquisition and integration expenses, purchase accounting adjustments	3	5	5	21	67	53	23	17
(Gain) loss on initial consolidation of subsidiaries	-	(12)	4	-	-	-	-	-
EBITDA from discontinued operations	(53)	6	5	5	10	6	6	5
(Gain) loss on disposition of businesses/assets	-	(40)	(3)	-	(3)	2	(128)	(137)
Loss on early extinguishment of debt	183	7	80	51	28	31	3	2
Extraordinary (gain) loss on the acquisition of a business	1	(4)	(2)	-	-	-	-	-
Certain legal settlements and related expense	8	46	11	9	3	4	3	3
Plant incident remediation costs (credits), net	-	-	-	-	-	4	1	10
(Income) expenses associated with merger	4	-	-	-	-	-	-	6
Amortization of pension and postretirement actuarial losses	25	31	43	74	51	74	65	76
Business separation costs			-	-	-	-	18	39
Restructuring, impairment, plant closing and transition costs	29	167	109	164	162	306	82	85
Adjusted EBITDA	900	1,245	1,439	1,213	1,340	1,221	1,127	1,270
Acquisition - ROC Performance Additives & TiO2[1]	191	306	168	110	155	-	-	-
Sale of European differentiated surfactants business[2]	(18)	(16)	(13)	(10)	(8)	(21)	(28)	(13)
Proforma adjusted EBITDA	$ 1,073	$ 1,535	$ 1,594	$ 1,313	$ 1,487	$ 1,200	$ 1,099	$ 1,257

(1) Pro forma adjusted to include the October 1, 2014 acquisition of the Performance Additives and Titanium Dioxide businesses of Rockwood Holdings, Inc. as if consummated at the beginning of the period; exclude the related sale of our TR52 product line to Henan Billions Chemicals Co., Ltd. in December 2014; and exclude the allocation of general corporate overhead by Rockwood.

(2) Pro forma adjusted for the sale of the European Surfactants business on December 30, 2016.

HUNTSMAN

Revenue, Adjusted EBITDA & Margin by Segment

($ in millions)	Pro Forma(3)	Pro Forma(3)	Pro Forma(3)	Pro Forma(3)	Pro Forma(3)	Pro Forma(3)	Pro Forma(3)	Pro Forma(3)		
Revenue	1Q15	2Q15	3Q15	4Q15	1Q16	2Q16	3Q16	4Q16	1Q17	2Q17
Polyurethanes	$ 890	$ 995	$ 1,017	$ 909	$ 836	$ 976	$ 891	$ 964	$ 953	$ 1,022
Performance Products	591	614	555	491	475	507	451	452	533	561
Advanced Materials	290	282	275	256	266	261	247	246	259	260
Textile Effects	206	216	196	186	185	198	184	184	188	205
Corporate, LIFO and other	(25)	(20)	(11)	(24)	(8)	(33)	-	(5)	(1)	6
Total	$ 1,952	$ 2,087	$ 2,032	$ 1,818	$ 1,754	$ 1,909	$ 1,773	$ 1,841	$ 1,932	$ 2,054
Pigments & Additives	572	592	543	453	540	576	532	491	537	562
Total with P&A	$ 2,524	$ 2,679	$ 2,575	$ 2,271	$ 2,294	$ 2,485	$ 2,305	$ 2,332	$ 2,469	$ 2,616

	Pro Forma(2)	Pro Forma(2)	Pro Forma(2)(3)	Pro Forma(2)(3)	Pro Forma(2)(3)	Pro Forma(3)	Pro Forma(3)	Pro Forma(3)
Revenue	2010	2011	2012	2013	2014	2015	2016	2Q17 LTM
Polyurethanes	$ 3,625	$ 4,456	$ 4,915	$ 4,991	$ 5,053	$ 3,811	$ 3,667	$ 3,830
Performance Products	2,160	2,679	2,574	2,566	2,695	2,251	1,885	1,997
Advanced Materials	1,244	1,372	1,325	1,267	1,248	1,103	1,020	1,012
Textile Effects	787	737	752	811	896	804	751	761
Corporate, LIFO and other	(258)	(265)	(285)	(251)	(219)	(80)	(46)	-
Total	$ 7,558	$ 8,979	$ 9,281	$ 9,384	$ 9,673	$ 7,889	$ 7,277	$ 7,600
Pigments & Additives	2,459	3,032	2,756	2,759	2,673	2,160	2,139	2,122
Total with P&A	$ 10,017	$ 12,011	$ 12,037	$ 12,143	$ 12,346	$ 10,049	$ 9,416	$ 9,722

($ in millions)	Pro Forma(3)	Pro Forma(3)	Pro Forma(3)	Pro Forma(3)	Pro Forma(3)	Pro Forma(3)	Pro Forma(3)	Pro Forma(3)		
Adjusted EBITDA(1)	1Q15	2Q15	3Q15	4Q15	1Q16	2Q16	3Q16	4Q16	1Q17	2Q17
Polyurethanes	$ 105	$ 159	$ 168	$ 141	$ 131	$ 171	$ 137	$ 130	$ 144	$ 167
Performance Products	115	135	117	72	85	78	63	62	84	102
Advanced Materials	58	58	56	48	60	58	55	50	54	56
Textile Effects	17	23	10	13	18	24	17	14	21	24
Corporate, LIFO and other	(37)	(31)	(50)	(38)	(42)	(45)	(45)	(52)	(43)	(50)
Total	$ 258	$ 344	$ 301	$ 236	$ 252	$ 286	$ 227	$ 204	$ 260	$ 299
Pigments & Additives	21	35	5	-	15	31	38	46	69	114
Total with P&A	$ 279	$ 379	$ 306	$ 236	$ 267	$ 317	$ 265	$ 250	$ 329	$ 413

	Pro Forma(2)	Pro Forma(2)	Pro Forma(2)(3)	Pro Forma(2)(3)	Pro Forma(2)(3)	Pro Forma(3)	Pro Forma(3)	Pro Forma(3)
Adjusted EBITDA(1)	2010	2011	2012	2013	2014	2015	2016	2Q17 LTM
Polyurethanes	$ 337	$ 495	$ 793	$ 746	$ 728	$ 573	$ 569	$ 578
Performance Products	353	365	356	393	465	439	288	311
Advanced Materials	144	114	98	131	199	220	223	215
Textile Effects	16	(64)	(20)	16	58	63	73	76
Corporate, LIFO and other	(186)	(193)	(171)	(188)	(188)	(156)	(184)	(190)
Total	$ 664	$ 717	$ 1,056	$ 1,098	$ 1,262	$ 1,139	$ 969	$ 990
Pigments & Additives	409	818	538	215	225	61	130	267
Total with P&A	$ 1,073	$ 1,535	$ 1,594	$ 1,313	$ 1,487	$ 1,200	$ 1,099	$ 1,257

	Pro Forma(3)	Pro Forma(3)	Pro Forma(3)	Pro Forma(3)	Pro Forma(3)	Pro Forma(3)	Pro Forma(3)	Pro Forma(3)		
Adj. EBITDA Margin	1Q15	2Q15	3Q15	4Q15	1Q16	2Q16	3Q16	4Q16	1Q17	2Q17
Polyurethanes	12%	16%	17%	16%	16%	18%	15%	13%	15%	16%
Performance Products	19%	22%	21%	15%	18%	15%	14%	14%	16%	18%
Advanced Materials	20%	21%	20%	19%	23%	22%	22%	20%	21%	22%
Textile Effects	8%	11%	5%	7%	10%	12%	9%	8%	11%	12%
Total	13%	16%	15%	13%	14%	15%	13%	11%	13%	15%
Pigments & Additives	4%	6%	1%	0%	3%	5%	7%	9%	13%	20%
Total with P&A	11%	14%	12%	10%	12%	13%	11%	11%	13%	16%

	Pro Forma(2)	Pro Forma(2)	Pro Forma(2)(3)	Pro Forma(2)(3)	Pro Forma(2)(3)	Pro Forma(3)	Pro Forma(3)	Pro Forma(3)
Adj. EBITDA Margin	2010	2011	2012	2013	2014	2015	2016	2Q17 LTM
Polyurethanes	9%	11%	16%	15%	14%	15%	16%	15%
Performance Products	16%	14%	14%	15%	17%	20%	15%	16%
Advanced Materials	12%	8%	7%	10%	16%	20%	22%	21%
Textile Effects	2%	-9%	-3%	2%	6%	8%	10%	10%
Total	9%	8%	11%	12%	13%	14%	13%	13%
Pigments & Additives	17%	27%	20%	8%	8%	3%	6%	13%
Total with P&A	11%	13%	13%	11%	12%	12%	12%	13%

(1) For a reconciliation see previous page.
(2) Pro forma adjusted to include the October 1, 2014 acquisition of the Performance Additives and Titanium Dioxide businesses of Rockwood Holdings, Inc. as if consummated at the beginning of the period, exclude the related sale of our TR52 product line to Henan Billions Chemicals Co., Ltd. in December 2014, and exclude the allocation of general corporate overhead by Rockwood.
(3) Pro forma adjusted for the sale of the European Surfactants business on December 30, 2016.

HUNTSMAN

HUNTSMAN

Enriching lives through innovation